Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05049863 · ClinicalTrials.gov registry record · Phase 1
Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT05049863 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 17 participants.
The verdict
NCT05049863, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The hypothesis is that the addition of mycophenolate mofetil (MMF) and allopurinol to chemotherapy in patients with relapsed small cell lung cancer (SCLC) will be safely tolerated and improve outcomes, as measured by response rate and progression-free survival in patients compared to other single agent chemotherapy drugs used in historical controls.
Interventions
- DRUG Irinotecan
- DRUG Mycophenolate Mofetil
- DRUG Allopurinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2024-11-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05049863
The ClinicalTrials.gov registry entry for NCT05049863 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Irinotecan is the first listed.
NCT05049863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05049863 about?
NCT05049863 is a clinical study titled "Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)". The hypothesis is that the addition of mycophenolate mofetil (MMF) and allopurinol to chemotherapy in patients with relapsed small cell lung cancer (SCLC) will be safely tolerated and improve outcomes, as measured by response rate and progression-free survival in patients compared to other single ag...
What is the current status of trial NCT05049863?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2023-02-27. Estimated completion is 2024-11-17.
What interventions are being tested in trial NCT05049863?
The interventions under investigation include: Irinotecan (DRUG), Mycophenolate Mofetil (DRUG), Allopurinol (DRUG).
Who is sponsoring clinical trial NCT05049863?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.